Ordaōs Raises $5 Million in Seed to Accelerate Drug Design and Discovery
Summary
Ordas creates novel mini-proteins that help pharma and biotechs around the world deliver safer and more effective life-saving treatments in a fraction of the time of traditional discovery methods. NEW YORK, Aug. 25, 2022 /PRNewswire/ -- Ordas, a biotechnology company designing novel mini-proteins to help drug hunters deliver life-saving treatments, today announced the completion of $5M in seed financing to aid in new product development and expand partner acquisition efforts. Ordas is a human-enabled, machine-driven drug design company that leverages proprietary multitask meta-learning and reinforcement learning to create mini-proteins that enable targeted therapies to reduce patient suffering, improve health, and extend life. Our flagship solution, miniPRO mini-proteins, enable drug hunters to deliver safer and more effective treatments in a fraction of the time of traditional discovery methods. VTC Ventures aims to partner with exceptional management teams to commercialize innovative technologies, accelerate growth, and build long-term value.